Cancer Research Technology
Log in Register
Menu

RMA.Trh4 Kb KO cells

Invented by Thorbald Van Hall at Leiden University Medical Center, Stichting Oncode Institute

Info

Catalogue Number 157678
Antigen/Gene or Protein Targets Trh4 Kb KO
Parental Line RMA
Host Mouse
Tissue Lymphatic Tissue
Disease Keywords Mouse Leukemia
Model Knock-Out
Relevance This cell line overexpresses the ER-resident ceramide synthase Trh4 and lacks the H2-Kb gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo‐antigen selectively presented by cells with processing defects in the classical MHC class I (MHC‐I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore can present the Trh4 peptide. Clear T cell recognition can be observed since the irrelevant MHC class I H2-Kb was knocked out.This population acts as a clear control.
Production Details Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/CAS9 technology
Research Area Cancer
Recommended Growing Conditions Suspension cells in DMEM+8% FCS
Positive Control RMA.Trh4 Db KO cells
Cellosaurus ID CVCL_J385

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.


Add a reference

References: 1 entry

Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.


Add a reference